Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)

被引：0
|
作者：
Bossi, P. [1 ]
Minuti, G. [2 ]
Brana, I. [3 ]
Garcia, V. Moreno [4 ]
Boni, V. [5 ]
Jamme, P. [6 ]
Call, J. A. [7 ]
Yan, C. [8 ]
Barasa, B. [9 ]
Doze, P. [10 ]
Joe, A. K. [11 ]
Laus, G. [11 ]
Daste, A. [12 ]
机构：
[1] IRCCS Humanitas Res Hosp, Med Oncol, Milan, Italy
[2] IRCCS Ist Nazl Tumori Regina Elena IRE, Phase & Precis Med Unit 1, Rome, Italy
[3] Vall Hebron Univ Hosp, Thorac Canc Unit, Barcelona, Spain
[4] Hosp Univ Fdn Jimenez Diaz, START Madrid, FJD Early Phase Clin Trials Unit, Madrid, Spain
[5] Hosp Univ Quironsalud Madrid, Oncol Dept, Pozuelo De Alarcon, Spain
[6] CHU Lille, Haut France, Ctr Hosp Reg Univ Lille, Lille, France
[7] South Texas Accelerated Res Therapeut START, Phase & Trials, San Antonio, TX USA
[8] Merus NV, Biostat, Utrecht, Netherlands
[9] Merus NV, Translat Res, Utrecht, Netherlands
[10] Merus NV, Clin Operat, Utrecht, Netherlands
[11] Merus NV, Clin Dev, Utrecht, Netherlands
[12] CHU Bordeaux, Hop St Andre, Med Oncol, Bordeaux, France
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.470
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
362P
引用
收藏
页码：S1610 / S1611
页数：2
相关论文
共 50 条
  • [31] A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck
    J.-P. Machiels
    P. Specenier
    J. Krauß
    A. Dietz
    M.-C. Kaminsky
    Y. Lalami
    M. Henke
    U. Keilholz
    R. Knecht
    N. J. Skartved
    I. D. Horak
    P. Pamperin
    S. Braun
    T. C. Gauler
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 13 - 20
  • [32] Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer
    van Gog, FB
    Brakenhoff, RH
    Stigter-van Walsum, M
    Snow, GB
    van Dongen, GAMS
    INTERNATIONAL JOURNAL OF CANCER, 1998, 77 (01) : 13 - 18
  • [33] A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX study
    Klinghammer, K.
    Fayette, J.
    Kawecki, A.
    Dietz, A.
    Schafhausen, P.
    Folprecht, G.
    Rottey, S.
    Debourdeau, P.
    Lavernia, J.
    Jacobs, A.
    Ahrens-Fath, I.
    Dietrich, B.
    Baumeister, H.
    Zurlo, A.
    Ochsenreither, S.
    Keilholz, U.
    ESMO OPEN, 2021, 6 (05)
  • [34] Association of Cell Signalling Factors With Survival and Anti-EGFR (Cetuximab) Resistance in Head and Neck Squamous Cell Carcinoma
    Semidey-Raven, Maria Eugenia
    Alberola-Ferranti, Margarita
    Giralt, Jordi
    Hernandez-Losa, Javier
    Rodriguez-Freixinos, Victor
    Benavente, Sergio
    Moline, Teresa
    Ramon y Cajal, Santiago
    MODERN PATHOLOGY, 2015, 28 : 330A - 330A
  • [35] Association of Cell Signalling Factors With Survival and Anti-EGFR (Cetuximab) Resistance in Head and Neck Squamous Cell Carcinoma
    Eugenia Semidey-Raven, Maria
    Alberola-Ferranti, Margarita
    Giralt, Jordi
    Hernandez-Losa, Javier
    Rodriguez-Freixinos, Victor
    Benavente, Sergio
    Moline, Teresa
    Ramon y Cajal, Santiago
    LABORATORY INVESTIGATION, 2015, 95 : 330A - 330A
  • [36] HGF and c-MET as potential orchestrators of invasive growth in head and neck squamous cell carcinoma
    De Herdt, Maria-Jantine
    de Jong, Robert J. Baatenburg
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2008, 13 : 2516 - 2526
  • [37] Tyrosine Kinase c-MET as Therapeutic Target for Radiosensitization of Head and Neck Squamous Cell Carcinomas
    Luettich, Lina
    Besso, Maria Jose
    Heiden, Stephan
    Koi, Lydia
    Baumann, Michael
    Krause, Mechthild
    Dubrovska, Anna
    Linge, Annett
    Kurth, Ina
    Peitzsch, Claudia
    CANCERS, 2021, 13 (08)
  • [38] Preclinical evaluation of IMGN289, an anti-EGFR antibody-maytansinoid conjugate for the treatment of squamous cell carcinoma of the head and neck
    Ponte, Jose F.
    Setiady, Yulius Y.
    Dong, Ling
    Skaletskaya, Anna
    Carrigan, Christina N.
    Anderson-Villaluz, Alfred
    Lutz, Robert J.
    Pinkas, Jan
    CANCER RESEARCH, 2013, 73 (08)
  • [39] Prospective multicenter phase II study of the anti-EGFR (epidermal growth factor receptor) antibody panitumumab (P) in patients with platinum pre-treated, advanced head and neck squamous cell cancer (HNSCC)
    Siano, M.
    Molinari, F.
    Martin, V.
    Mach, N.
    Frueh, M.
    Crippa, S.
    Ghielmini, M.
    Frattini, M.
    Espeli, V.
    Oncology Research and Treatment, 2015, 38 : 25 - 25
  • [40] Preliminary antitumor activity of MCLA-158, an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell carcinoma
    Hollebecque, Antoine
    Brana, Irene
    Iglesias, Lara
    Even, Caroline
    Shumei, Kato
    Garcia, Marc Diez
    Bover, Mateo
    Martin-Romano, Patricia
    Garcia-Carbonero, Rocio
    Argiles, Guillen
    Tabernero, Josep
    Khanna, Rajan
    Stalbovskaya, Viktoriya
    van Bueren, Jeroen Lammerts
    Bol, Kees
    Bekradda, Mohamed
    Joe, Andrew
    Wasserman, Ernesto
    Cohen, Ezra E. W.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
12345